Functional significance of a C–>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine
Open accessAbstract
AIMS: The cytochrome P450 enzyme CYP1A2 metabolises several drugs and carcinogens. We wanted to determine how much of the variability of CYP1A2 activity is explained by a newly discovered gene polymorphism in intron 1. METHODS: A single nucleotide polymorphism in intron 1 of the CYP1A2 gene at position 734 downstream of the first transcribed nucleotide was identified by DNA sequence analysis. The functional significance of this C/A polymorphism was assessed in 185 healthy Caucasian non-smokers and in 51 smokers by genotyping and phenotyping using caffeine (100 mg oral dose). RESULTS: Out of the total sample, 46% were homozygous for the variant A, 44% were heterozygous, and 10% were homozygous for the variant C. The ratio of 1,7-dimethylxanthine (17X) plus 1,7-dimethyluric acid divided by caffeine in 0-5 h urine samples from 185 non-smokers did not differ significantly between the three CYP1A2 genotypes. In the 51 smokers, analysis of variance revealed significant differences in the 5 h plasma 17X/caffeine ratios between the genotypes (P=0.008, F-test). The mean ratio was 1.37 in carriers of the A/A genotype, 0.88 in heterozygotes and 0.82 in carriers of C/C. The mean difference between the A/A and C/A groups was 0.48 (95% confidence interval 0. 15-0.81; P=0.01). CONCLUSIONS: The A/A genotype, which may represent a CYP1A2 high inducibility genotype, may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. Further studies are needed to define the role of this polymorphism on the pharmacokinetics of drugs metabolised by CYP1A2 and in the activation of carcinogens.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
At least 150 single-nucleotide polymorphisms can accelerate caffeine clearance.
“At least 150 single-nucleotide polymorphisms can accelerate caffeine clearance (50).”
From The Safety of Ingested Caffeine: A Comprehensive Review (2017) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bertz, R., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755 · see citing works
Butler, M. A., Lang, N. P., Young, J. F., Caporaso, N. E., Vineis, P., Hayes, R. B., Teitel, C. H., Massengill, J., Lawsen, M. F., & Kadlubar, F. F. (1992) · Pharmacogenetics · doi:10.1097/00008571-199206000-00003 · Cited by 419 · see citing works
Nomenclature for human CYP2D6 alleles
Daly, A. K., Brockmöller, J., Broly, F., Eichelbaum, M. F., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman‐Sundberg, M., Ishizaki, T., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199606000-00001 · Cited by 396 · see citing works
Eaton, D. L., Gallagher, E. P., Bammler, T. K., & Kunze, K. L. (1995) · Pharmacogenetics · doi:10.1097/00008571-199510000-00001 · Cited by 271 · see citing works
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities
KALOW, W., & Tang, B.-K. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.176 · Cited by 264 · see citing works
A simple test for acetylator phenotype using caffeine.
Grant, D. M., Tang, B., & KALOW, W. (1984) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1984.tb02372.x · Cited by 212 · see citing works
Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva
Fuhr, U., & Rost, K. L. (1994) · Pharmacogenetics · doi:10.1097/00008571-199406000-00001 · Cited by 182 · see citing works
Ikeya, K., Jaiswal, A. K., Owens, R. A., Jones, J. E., Nebert, D. W., & Kimura, S. (1989) · Molecular Endocrinology · doi:10.1210/mend-3-9-1399 · Cited by 147 · see citing works
Nakajima, M., Yokoi, T., Mizutani, M., Shin, S., Kadlubar, F. F., & Kamataki, T. (1994) · PubMed · Cited by 141 · see citing works
Rost, K. L., Brösicke, H., Brockmöller, J., Scheffler, M., Helge, H., & Roots, I. (1992) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1992.126 · Cited by 132 · see citing works
Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment
Rostami‐Hodjegan, A., Nurminen, S., Jackson, P. R., & Tucker, G. (1996) · Pharmacogenetics · doi:10.1097/00008571-199604000-00001 · Cited by 125 · see citing works
Coleman, T., Ellis, S. W., Martin, I. J., Lennard, M. S., & Tucker, G. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12922-4 · Cited by 96 · see citing works
Polymorphisms of CYP1A1 and GSTM1 influence the in vivo function of CYP1A2
Macleod, S. L., Sinha, R. R., Kadlubar, F. F., & Lang, N. P. (1997) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(97)00036-5 · Cited by 61 · see citing works
Heterocyclic amines: evaluation of their role in diet associated human cancer
Gooderham, N. J., MURRAY, S., Lynch, A. M., EDWARDS, R. J., Yadollahi‐Farsani, M., Bratt, C., Rich, K. J., Zhao, K., Murray, B. P., Bhadresa, S., et al. (1996) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1996.37513.x · Cited by 46 · see citing works
A population and family study of CYP1A2 using caffeine urinary metabolites
Catteau, A., Poisson, N., Bona�ti-Pelli�, C., Bechtel, Y. C., & Bechtel, P. R. (1995) · European Journal of Clinical Pharmacology · doi:10.1007/bf00196856 · Cited by 45 · see citing works
Yokoi, T., Sawada, M., & Kamataki, T. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512001-00003 · Cited by 17 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a J Pharmacol Exp Ther 1996; 277: 685-690. laboratory manual, 2nd ed., Cold Spring Harbor Laboratory 3
- Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, cancer. Br J Clin Pharmacol 1996; 42: 91-98.
Cited by
Sorted by citations
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · see citing works
Genome-wide association study identifies eight loci associated with blood pressure
Wellcome Trust Case Control Consortium, Newton-Cheh, C., Johnson, T., Gateva, V., Tobin, M. D., Bochud, M., Coin, L., Najjar, S. S., Zhao, J. H., Heath, S. C., et al. (2009) · Nature Genetics · doi:10.1038/ng.361 · Cited by 1,215 · see citing works
Ingelman‐Sundberg, M., Sim, S. C., Gomez, A. V., & Rodríguez‐Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,165 · see citing works
Coffee and Health: A Review of Recent Human Research
Higdon, J. V., & Frei, B. (2006) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390500400009 · Cited by 1,090 · see citing works
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S., Liu, J., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 832 · see citing works
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 727 · see citing works
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632 · see citing works
Scientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613 · see citing works
“A single base change of A to C at position 734 within intron 1 of the CYP1A2 gene decreases inducibility of the enzyme (Sachse et al., 1999; Han et al., 2001).”
BackgroundFunctional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. G. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593 · see citing works
Cytochrome P450 pharmacogenetics and cancer
Rodríguez‐Antona, C., & Ingelman‐Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 574 · see citing works
Bartsch, H., Nair, U., Risch, A., Rojas, M., Wikman, H., & Alexandrov, K. (2000) · PubMed · Cited by 569 · see citing works
Inhibition and induction of human cytochrome P450 enzymes: current status
Pelkonen, O., Turpeinen, M., Hakkola, J., Honkakoski, P., Hukkanen, J., & Raunio, H. (2008) · Archives of Toxicology · doi:10.1007/s00204-008-0332-8 · Cited by 571 · see citing works
The Safety of Ingested Caffeine: A Comprehensive Review
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00080 · Cited by 557 · see citing works
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment
Ingelman‐Sundberg, M., Oscarson, M., & McLellan, R. A. (1999) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(99)01363-2 · Cited by 539 · see citing works
Clark, I., & Landolt, H. P. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2016.01.006 · Cited by 499 · see citing works
Coffee, CYP1A2 genotype, and risk of myocardial infarction
Cornelis, M. C., El-Sohemy, A., Kabagambe, E. K., & Campos, H. (2006) · JAMA · doi:10.1001/jama.295.10.1135 · Cited by 490 · see citing works
Population genetic structure of variable drug response
Wilson, J. F., Weale, M. E., Smith, A. C., Gratrix, F., Fletcher, B., Thomas, M., Bradman, N. N., & Goldstein, D. B. (2001) · Nature Genetics · doi:10.1038/ng761 · Cited by 460 · see citing works
Applications of CYP450 Testing in the Clinical Setting
Samer, C. F., Lorenzini, K. I., Rollason, V., Daali, Y., & Desmeules, J. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0028-5 · Cited by 355 · see citing works
Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research
Arranz, M. J., & de León, J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002009 · Cited by 354 · see citing works
Astorino, T., & Roberson, D. W. (2010) · Journal of Strength and Conditioning Research · doi:10.1519/jsc.0b013e3181c1f88a · Cited by 335 · see citing works
Genetics of caffeine consumption and responses to caffeine
Yang, A., Palmer, A. A., & de Wit, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1900-1 · Cited by 310 · see citing works
Assessment of CYP1A2 Activity in Clinical Practice: Why, How, and When?
Faber, M. S., Jetter, A., & Fuhr, U. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto_973160.x · Cited by 284 · see citing works
Cytochrome P450 variations in different ethnic populations
McGraw, J. E., & Waller, D. P. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.657626 · Cited by 284 · see citing works
Sachse, C. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1839 · Cited by 284 · see citing works
Rostami‐Hodjegan, A., Amin, A. M., Spencer, E. P., Lennard, M. S., Tucker, G. T., & Flanagan, R. J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000106221.36344.4d · Cited by 279 · see citing works
Ghotbi, R., Christensen, M., Roh, H., Ingelman‐Sundberg, M., Aklillu, E., & Bertilsson, L. (2007) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-007-0288-2 · Cited by 265 · see citing works
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J. (2009) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262 · see citing works
Southward, K., Rutherfurd-Markwick, K. J., & Ali, A. (2018) · Sports Medicine · doi:10.1007/s40279-018-0939-8 · Cited by 254 · see citing works
Gunes, A., & Dahl, M. (2008) · Pharmacogenomics · doi:10.2217/14622416.9.5.625 · Cited by 257 · see citing works
Smoking in Patients Receiving Psychotropic Medications: A Pharmacokinetic Perspective
Desai, H. D., Seabolt, J., & Jann, M. W. (2001) · CNS Drugs · doi:10.2165/00023210-200115060-00005 · Cited by 253 · see citing works
Time response of cytochrome P450 1A2 activity on cessation of heavy smoking*1
Faber, M. S. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.04.003 · Cited by 251 · see citing works
Crettol, S., Déglon, J., BESSON, J., Croquette-Krokar, M., Hämmig, R., Gothuey, I., Monnat, M., & Eap, C. B. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.012 · Cited by 249 · see citing works
Rasmussen (2002) · Pharmacogenetics · doi:10.1097/00008571-200208000-00008 · Cited by 241 · see citing works
Zhou, S. F., Yang, L.-P., Zhou, Z.-W., Liu, Y., & Chan, E. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9127-y · Cited by 239 · see citing works
Genetic polymorphism of the adenosine A2A receptor is associated with habitual caffeine consumption
Cornelis, M. C., El‐Sohemy, A., & Campos, H. (2007) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.1.240 · Cited by 231 · see citing works
CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension
Palatini, P., Ceolotto, G., Ragazzo, F., Dorigatti, F., Saladini, F., Papparella, I., Mos, L., Zanata, G., & Santonastaso, M. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832ba850 · Cited by 230 · see citing works
Caffeine Consumption through Coffee: Content in the Beverage, Metabolism, Health Benefits and Risks
DePaula, J., & Farah, A. (2019) · Beverages · doi:10.3390/beverages5020037 · Cited by 240 · see citing works
Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and Atherosclerosis
Elfaki, I., Mir, R., Almutairi, F. M., & Abuduhier, F. M. (2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.8.2057 · Cited by 218 · see citing works
Pickering, C., & Kiely, J. (2017) · Sports Medicine · doi:10.1007/s40279-017-0776-1 · Cited by 221 · see citing works
Lampe, J. W., & Trudo, S. P. (2002) · Journal of Nutrition · doi:10.1093/jn/131.10.2991 · Cited by 203 · see citing works
Božina, N., Bradamante, V., & Lovrić, M. (2009) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/10004-1254-60-2009-1885 · Cited by 201 · see citing works
Sex-specific differences in CYP450 isoforms in humans
Scandlyn, M. J., Stuart, E. C., & Rosengren, R. J. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.4.413 · Cited by 199 · see citing works
Stingl, J., Brockmöller, J., & Viviani, R. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.42 · Cited by 200 · see citing works
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 195 · see citing works
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195 · see citing works
A Highly Selective Ratiometric Two-Photon Fluorescent Probe for Human Cytochrome P450 1A
Dai, Z., Ge, G., Feng, L., Ning, J., Hu, L., Jin, Q., Wang, D., Lv, X., Dou, T., Cui, J., et al. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b09854 · Cited by 194 · see citing works
Pharmacogenetics of the major polymorphic metabolizing enzymes
Daly, A. K. (2003) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2003.00119.x · Cited by 189 · see citing works
Caffeine as a factor influencing the functioning of the human body-friend or foe?
Rodak, K., Kokot, I., & Kratz, E. M. (2021) · Nutrients · doi:10.3390/nu13093088 · Cited by 188 · see citing works
Cytochrome P450 in Pharmacogenetics: An Update
Tornio, A., & Backman, J. T. (2018) · Advances in pharmacology · doi:10.1016/bs.apha.2018.04.007 · Cited by 182 · see citing works
Aklillu, E., Carrillo, J. A., Makonnen, E., Hellman, K., Pitarque, M., Bertilsson, L., & Ingelman‐Sundberg, M. (2003) · Molecular Pharmacology · doi:10.1124/mol.64.3.659 · Cited by 181 · see citing works
Zordoky, B. N. M., & El‐Kadi, A. O. S. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.002 · Cited by 179 · see citing works
The influence of a CYP1A2 polymorphism on the ergogenic effects of caffeine
Womack, C. J., Saunders, M. J., Bechtel, M. K., Bolton, D. J., Martin, M., Luden, N. D., Dunham, W., & Hancock, M. (2012) · Journal of the International Society of Sports Nutrition · doi:10.1186/1550-2783-9-7 · Cited by 178 · see citing works
The effect of variable cigarette consumption on the interaction with clozapine and olanzapine
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., & Refsum, H. (2006) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-006-0209-9 · Cited by 178 · see citing works
Carrillo, J. A., Herráiz, A. G., Ramos, S., Gervasini, G., Vizcaíno, S., & Benítez, J. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200304000-00003 · Cited by 177 · see citing works
van der Weide, J., Steijns, L. S. W., & van Weelden, M. J. M. (2003) · Pharmacogenetics · doi:10.1097/00008571-200303000-00006 · Cited by 176 · see citing works
Wilson, Z., Rostami‐Hodjegan, A., Burn, J. L., Tooley, A., Boyle, J., Ellis, S. W., & Tucker, G. T. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01881.x · Cited by 175 · see citing works
Sachse, C., Bhambra, U., Smith, G. C., Lightfoot, T. J., Barrett, J. H., Scollay, J., Garner, R. C., Boobis, A. R., Wolf, C. R., Gooderham, N. J., et al. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01733.x · Cited by 173 · see citing works
Caffeine and Exercise: What Next?
Pickering, C., & Grgić, J. (2019) · Sports Medicine · doi:10.1007/s40279-019-01101-0 · Cited by 173 · see citing works
Grosso, L. M., & Bracken, M. B. (2005) · Annals of Epidemiology · doi:10.1016/j.annepidem.2004.12.011 · Cited by 173 · see citing works
Genetic susceptibility to adverse effects of drugs and environmental toxicants
Ingelman‐Sundberg, M. (2001) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/s0027-5107(01)00205-6 · Cited by 170 · see citing works
Basile, V. S., Özdemir, V., Masellis, M., Walker, M. L., Meltzer, H. Y., Lieberman, J. A., Potkin, S. G., Alva, G., KALOW, W., Macciardi, F. M., et al. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000736 · Cited by 168 · see citing works
Cytochrome P450 Phenotyping/Genotyping in Patients Receiving Antipsychotics
Dahl, M. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241070-00001 · Cited by 163 · see citing works
Pharmacogenetics-based therapeutic recommendations — ready for clinical practice?
Kirchheiner, J., Fuhr, U., & Brockmöller, J. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1801 · Cited by 160 · see citing works
Goodman, M. T., McDuffie, K., Kolonel, L. N., Terada, K. Y., Donlon, T. A., Wilkens, L. R., Guo, C., & Marchand, L. L. (2001) · PubMed · Cited by 157 · see citing works
Cytochrome P450 enzyme polymorphisms and adverse drug reactions
Pirmohamed, M., & Park, B. K. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00247-6 · Cited by 152 · see citing works
The role of genetic polymorphisms in environmental health.
Kelada, S. N., Eaton, D. L., WANG, S. S., Rothman, N., & Khoury, M. J. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6065 · Cited by 150 · see citing works
Landi, S., Gemignani, F., Moreno, V. R., Gioia‐Patricola, L., Chabrier, A., Guinó, E., Navarro, M., de, J., Capellá, G., & Canzian, F. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000165904.48994.3d · Cited by 148 · see citing works
ABCB1 and Cytochrome P450 Polymorphisms
Sirot, E. J., Knežević, B., Morena, P., Harenberg, S., Oneda, B., Crettol, S., Ansermot, N., Baumann, P., & Eap, C. B. (2009) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181acc372 · Cited by 148 · see citing works
Dietary Phytoestrogen Intake Is Associated with Reduced Colorectal Cancer Risk
Cotterchio, M., Boucher, B. A., Manno, M., Gallinger, S., Okey, A. B., & Harper, P. A. (2006) · Journal of Nutrition · doi:10.1093/jn/136.12.3046 · Cited by 149 · see citing works
Clinical applications of CYP genotyping in psychiatry
Spina, E., & de León, J. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1300-5 · Cited by 146 · see citing works
Sequence variants at CYP1A1–CYP1A2 and AHR associate with coffee consumption
Sulem, P., Gudbjartsson, D. F., Geller, F., Prokopenko, I., Feenstra, B., Aben, K. K. H., Franke, B., den Heijer, M., Kovacs, P. L., Stümvoll, M., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr086 · Cited by 145 · see citing works
Role of the aryl hydrocarbon receptor in drug metabolism
Ramadoss, P., Marcus, C. B., & Perdew, G. H. (2005) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.1.1.9 · Cited by 144 · see citing works
Bakker, P. R., van Harten, P. N., & van Os, J. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002142 · Cited by 144 · see citing works
Thorn, C. F., Aklillu, E., Klein, T. E., & Altman, R. B. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834c6efd · Cited by 141 · see citing works
kConFab Investigators, Amin, N., Byrne, E. M., Johnson, J., Chenevix‐Trench, G., Walter, S., Nolte, I. M., Vink, J. M., Rawal, R., Mangino, M., et al. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.101 · Cited by 139 · see citing works
Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism
Donato, M. T., & Castell, J. V. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342020-00004 · Cited by 138 · see citing works
Phenotypic polymorphism and gender‐related differences of CYP1A2 activity in a Chinese population
Ou‐Yang, D., Huang, S., Wang, W., Xie, H., Xu, Z., Shu, Y., & Zhou, H. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00128.x · Cited by 133 · see citing works
Williams, J. A., Martin, F. L., Muir, G., Hewer, A. J., Grover, P. L., & Phillips, D. H. (2000) · Carcinogenesis · doi:10.1093/carcin/21.9.1683 · Cited by 128 · see citing works
What Should We Do about Habitual Caffeine Use in Athletes?
Pickering, C., & Kiely, J. (2019) · Sports Medicine · doi:10.1007/s40279-018-0980-7 · Cited by 127 · see citing works
Precision (Personalized) Nutrition: Understanding Metabolic Heterogeneity
Zeisel, S. H. (2020) · Annual Review of Food Science and Technology · doi:10.1146/annurev-food-032519-051736 · Cited by 130 · see citing works
Nonresponse to Clozapine and Ultrarapid CYP1A2 Activity
Eap, C. B., Bender, S., Sirot, E. J., Cucchia, G., Jonzier-Perey, M., Baumann, P., Allorge, D., & Broly, F. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000116646.91923.2f · Cited by 125 · see citing works
Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation
Corchero, J., Pimprale, S., Kimura, S., & Gonzalez, F. J. (2001) · Pharmacogenetics · doi:10.1097/00008571-200102000-00001 · Cited by 125 · see citing works
Murray, M. T. (2006) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.58.7.0001 · Cited by 124 · see citing works
Pharmacogenomics in schizophrenia: the quest for individualized therapy
Basile, V. S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2517 · Cited by 124 · see citing works
Effects of red bull energy drink on repeated sprint performance in women athletes
Astorino, T. A., Matera, A. J., Basinger, J., Evans, M., Schurman, T., & Marquez, R. (2011) · Amino Acids · doi:10.1007/s00726-011-0900-8 · Cited by 120 · see citing works
Zhou, A., & Hyppönen, E. (2018) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/nqy297 · Cited by 120 · see citing works
Ensom, M. H. H., Chang, T. K. H., & Patel, P. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140110-00001 · Cited by 119 · see citing works
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease
Popat, R. A., Eeden, S. K. V. D., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K. S., Mayeux, R. P., Ritz, B. R., Ross, G. W., Petrovitch, H., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03353.x · Cited by 119 · see citing works
Estrogen Metabolism–Related Genes and Breast Cancer Risk: The Multiethnic Cohort Study
Marchand, L. L., Donlon, T. A., Kolonel, L. N., Henderson, B. E., & Wilkens, L. R. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0076 · Cited by 118 · see citing works
Chida, M., Yokoi, T., Fukui, T., Kinoshita, M., Yokota, J., & Kamataki, T. (1999) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1999.tb00832.x · Cited by 118 · see citing works
Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility
Dobrinas, M., Cornuz, J., Oneda, B., Serra, M. K., Puhl, M., & Eap, C. B. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.70 · Cited by 117 · see citing works
Pharmacogenetics of antidepressants
Crisafulli, C., Fabbri, C., Porcelli, S., Drago, A., Spina, E., De Ronchi, D., & Serretti, A. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00006 · Cited by 113 · see citing works
Coffee, caffeine, and coronary heart disease
Cornelis, M. C., & El‐Sohemy, A. (2007) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e3282f05d81 · Cited by 113 · see citing works
Peck, J. D., Leviton, A., & Cowan, L. D. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2010.06.019 · Cited by 112 · see citing works
Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women
Sangrajrang, S., Sato, Y., Sakamoto, H., Ohnami, S., Laird, N. M., Khuhaprema, T., Brennan, P., Boffetta, P., & Yoshida, T. (2009) · International Journal of Cancer · doi:10.1002/ijc.24434 · Cited by 112 · see citing works
Therapeutic Drug Monitoring and Pharmacogenetic Tests as Tools in Pharmacovigilance
Sirot, E. J., van der Velden, J. W., Rentsch, K., Eap, C. B., & Baumann, P. (2006) · Drug Safety · doi:10.2165/00002018-200629090-00001 · Cited by 112 · see citing works
Biological roles of cytochrome P450 1A1, 1A2, and 1B1 enzymes
Kwon, Y., Shin, S., & Chun, Y. (2021) · Archives of Pharmacal Research · doi:10.1007/s12272-021-01306-w · Cited by 111 · see citing works
Genetic polymorphisms in heterocyclic amine metabolism and risk of colorectal adenomas
Ishibe, N., Sinha, R. R., Hein, D. W., Kulldorff, M., Strickland, P. T., Fretland, A. J., Chow, W., Kadlubar, F. F., Lang, N. P., & Rothman, N. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00008 · Cited by 111 · see citing works
Kamali, F., & Wynne, H. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.070808.170037 · Cited by 109 · see citing works
- Authors
- Sachse, C., Brockmöller, J., Bauer, S., & Roots, I.
- Affiliations
- Humboldt-Universität zu Berlin (DE)
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1999-04
- Volume
- 47
- Issue
- 4
- Pages
- 445-449
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- PMC
- PMC2014233
- OpenAlex
- W1734451748
- Cited by
- 751
- References
- 16
- Citations by year
- 2026: 12 · 2025: 21 · 2024: 27 · 2023: 27 · 2022: 18 · 2021: 21 · 2020: 39 · 2019: 17 · 2018: 30 · 2017: 20 · 2016: 31 · 2015: 27 · 2014: 27 · 2013: 26 · 2012: 42
- FWCI
- 19.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- British Journal of Clinical Pharmacology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology › Coffee research and impacts
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- CYP1A2, cytochrome P450, intron 1 polymorphism, caffeine, 1,7-dimethylxanthine, enzyme inducibility, smokers, genetic variation in drug metabolism, pharmacogenetics, carcinogen activation
- MeSH terms
- Caffeine, Humans, Introns, Polymorphism, Genetic, Smoking, Cytochrome P-450 CYP1A2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
